Today’s Research Reports on Stocks to Watch: Johnson & Johnson and InVivo Therapeutics
NEW YORK, NY / ACCESSWIRE / March 9, 2018 / Shares of Johnson & Johnson saw a slight close in the green yesterday despite announcing that the average price paid for its medicines had dropped last year. The company still saw revenues grow 4.6% however in 2017. Shares of InVivo were skyrocketing after the company made an announcement about the FDA approving supplemental Investigational Device Exemption for a second clinical study of its Neuro-Spinal Scaffold™ in patients with acute spinal cord injury (SCI).
RDI Initiates Coverage on:
Johnson & Johnson
https://rdinvesting.com/news/?ticker=JNJ
InVivo Therapeutics Holdings Corp.
https://rdinvesting.com/news/?ticker=NVIV
Johnson & Johnson shares closed up 2.34% on Thursday with nearly 6.5 million shares traded. The company announced yesterday that the average price paid for its medicines in the U.S. fell by 4.6% in 2017. It was in January however that the company reported its fourth quarter financial report which topped in earnings and revenues. The company's CEO Alex Gorsky said at the time, "Johnson & Johnson delivered strong adjusted earnings per share growth of 8.5% and total shareholder return of greater than 24% in 2017, driven by the robust performance of our Pharmaceutical business, while continuing to make investments in acquisitions, innovation and strategic partnerships to accelerate growth in each of our businesses. As we enter 2018 and look beyond, we are experiencing an incredible pace of change in health care. Johnson & Johnson is uniquely positioned to lead during this dynamic era and deliver innovative solutions for patients and consumers that drive sustainable, long-term growth. We are pleased with the passage of recent legislation modernizing the U.S. tax system, which enables Johnson & Johnson to invest in innovation at higher levels to help address the most challenging unmet medical needs facing health care today."
Access RDI's Johnson & Johnson Research Report at:
https://rdinvesting.com/news/?ticker=JNJ
InVivo Therapeutics Holdings Corp. shares exploded on Thursday and closed the day up 49.37% on about 16.3 million shares traded. The average trading volume for the stock is a little under 300,000 shares. The company announced yesterday that it has received supplemental Investigational Device Exemption (IDE) approval from the FDA for a second pivotal clinical study of its Neuro-Spinal Scaffold™ in patients with acute spinal cord injury (SCI). CEO Richard Toselli, M.D., stated, "We are pleased to announce the FDA's approval of this randomized, controlled trial and appreciate the agency's collaboration with us on the development of a protocol to address the substantial unmet needs in this patient population. We believe this now sets us in a direction towards a clear and efficient path to approval under the HDE regulatory program, and we are focused on engaging with the investment community and exploring financing mechanisms to support this approved randomized study. We look forward to providing further updates as we obtain clarity on financing and the timing for our second pivotal trial." He added, "InVivo has achieved important milestones with the FDA over the past seven months under Dr. Toselli's leadership," stated Ann Merrifield, InVivo's Chair of the Board of Directors. "I wish to commend Rich and his team in their continuing interactions with the FDA and their strategy for advancing this important program in the clinic."
Access RDI's InVivo Therapeutics Holdings Corp. Research Report at:
https://rdinvesting.com/news/?ticker=NVIV
Our Actionable Research on Johnson & Johnson (NYSE: JNJ) and InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
